Virtual Library

Start Your Search

  • WCLC 2013

    15th World Conference on Lung Cancer

    Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.

    Presentation Date(s):  
    • October 27 - 30, 2013
    • Total Presentations: 2517

Filter Results:

Show Only Available Presentations

  • +

    Y - Young Investigator & First Time Attendee Session

    • Type: Other Sessions
    • Track: Other Topics
    • Presentations: 8
    • Moderators:M. Edelman
    • Coordinates: 10/27/2013, 08:00 - 11:30, Parkside Ballroom A+B, Level 1
  • +

    HOD2 - Mondays Highlights of the Day - Medical Oncology, Biology and Pathology

    • Type: Highlight of the Day Session
    • Track: Medical Oncology
    • Presentations: 3
    • Moderators:R. Pirker
    • Coordinates: 10/29/2013, 07:00 - 08:00, Bayside Auditorium B, Level 1
  • +

    MO13 - SCLC I

    • Type: Mini Oral Abstract Session
    • Track: Medical Oncology
    • Presentations: 11
    • Moderators:C.K. Liam
    • Coordinates: 10/29/2013, 10:30 - 12:00, Bayside 201 - 203, Level 2
    • +

      MO13.01 - Disease control rate at 8 weeks predicts subsequent survival in platinum-treated extensive stage small cell lung cancer (ES-SCLC): a patient level analysis of SWOG trials

      10:30 - 10:35  |  Author(s): P. Lara

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    MO18 - NSCLC - Targeted Therapies IV

    • Type: Mini Oral Abstract Session
    • Track: Medical Oncology
    • Presentations: 13
    • Moderators:L. Horn
    • Coordinates: 10/29/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
    • +

      MO18.11 - Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in a phase 1/1B trial involving KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results

      17:15 - 17:20  |  Author(s): J. Bennouna

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    O21 - SCLC II

    • Type: Oral Abstract Session
    • Track: Medical Oncology
    • Presentations: 8
    • Moderators:M. Ahn
    • Coordinates: 10/29/2013, 16:15 - 17:45, Parkside Ballroom B, Level 1
    • +

      O21.01 - A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC)

      16:15 - 16:25  |  Author(s): M.J. Seckl

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      O21.02 - Phase III trial comparing irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP) in Korean patients with extensive disease (ED) small cell lung cancer (SCLC)

      16:25 - 16:35  |  Author(s): D. Kim

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      O21.03 - N-0923, A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: Alliance (NCCTG) Study

      16:35 - 16:45  |  Author(s): A. Adjei

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      O21.04 - DISCUSSANT

      16:45 - 17:00  |  Author(s): N. Murray

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      O21.05 - A multicenter, double-blind, placebo-controlled, randomized phase 2 study of ganitumab or rilotumumab with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC)

      17:00 - 17:10  |  Author(s): B. Glisson

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      O21.06 - MLN8237 (alisertib), a selective Aurora A Kinase (AAK) inhibitor, in patients with relapsed/refractory small cell lung cancer (SCLC): Phase 2 results

      17:10 - 17:20  |  Author(s): L. Havel

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      O21.07 - A new prognostic model for relapsed/refractory extensive stage small cell lung cancer (ES-SCLC) derived from prospective SWOG trials: implications for study design

      17:20 - 17:30  |  Author(s): P. Lara

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      O21.08 - DISCUSSANT

      17:30 - 17:45  |  Author(s): K. Kelly

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    MO20 - Preclinical Therapeutic Models II

    • Type: Mini Oral Abstract Session
    • Track: Biology
    • Presentations: 10
    • Moderators:P. Waring
    • Coordinates: 10/30/2013, 10:30 - 12:00, Bayside Gallery B, Level 1
    • +

      MO20.04 - Divergent activity of afatinib (AFAT) and cetuximab (CET) in patient-derived xenograft (PDX) models of acquired erlotinib resistance.

      10:45 - 10:50  |  Author(s): P. Mack

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.